Every Thursday we send out a curated newsletter on “all things femtech”. This is the latest edition. If you’re interested in subscribing, you can do so at the bottom of this page.
“Germany’s Bayer, the drugs and pesticides maker, has inked a deal to buy a British biotech firm to boost its women’s healthcare business, with an initial $425 million payment agreed.” (Source: Guardian)
Highlights
Bayer is acquiring menopause biotech company KaNDy Therapeutics; Nurx adds $22.5M in new funding and announces plans for new migraine treatments; Stix, a startup offering D2C pregnancy & ovulation tests, raises a $1.3M seed round; Women’s health startup Kliit Health rebrands as Kiira; Equip launches a virtual eating disorder treatment program; Zomato, one of India’s biggest food delivery companies, is introducing a ‘period leave’ program, GoodRx files for IPO; ‘Disgusting’ study rating the attractiveness of women with endometriosis is finally retracted after 7 years
You’ve found some of our exclusive Inner Circle Content.
This article is only available for our Inner Circle Members. To read on:
Kathrin Folkendt is the Founder & CEO of Femtech Insider, the globally leading publication on all things femtech. She usually writes about women's health innovation, health equity, and entrepreneurship.
